课题基金 / 基金详情

Stat 1 modification for antiviral defense

Stat 1 modification for antiviral defense
抗病毒防御的 Stat 1 修改
批准号:
8234937
负责人:
Michael J Holtzman
金额:
$38.33万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-03-01 至 2014-02-28

项目摘要

项目成果

Michael J Holtzman的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Viruses are among the most frequent causes of acute and chronic illness, and newly discovered viruses continue to cause emergent diseases that resist established vaccines. Despite the scope of this problem, the accuracy of diagnosis and efficacy of treatment for most viral infections, especially new types of infections, is very limited in effectiveness. To address this issue, we have developed an alternative strategy that is aimed at defining and then improving the antiviral host response. We focus particularly on respiratory infection since this is a common route of natural infection and a likely route for delivery of bioterrorist threats. In that regard, we have developed a system for primary-culture and infection of human airway epithelial cells that exhibits high fidelity to behavior found in vivo. Our analysis of this epithelial cell model in concert with a corresponding mouse model indicates that antiviral defense against respiratory viral infection depends critically on interferon (IFN) activation of the Stall signaling molecule in airway epithelial cells. Based on these findings, we proposed that improving Stall function in airway epithelial cells would enhance antiviral defense. Accordingly, we engineered a modified Stall with strategic double-cysteine mutalions (designaled Slal1-CC) that is hyperresponsive to endogenous interferon levels. Expression of Stall-CC should thereby enhance interferon-signaling function and provide for better control of viral replication. Indeed, our Preliminary Studies demonstrate that Stall-CC expression markedly decreases Ihe level of viral replication both in vitro (using transduced cells) and in vivo (using transgenic or gene transfer technology). For example, mice carrying the Stall-CC transgene or treated with a Stall-CC gene-transfer vector are fully protected against otherwise lethal infections due to each of the three viruses studied thus far. Furthermore, we have observed no toxicities of Stall-CC expression, in contrast to the situation for direct administralion or overexpression of interferon itself. In this proposal, we aim to extend our approach to the study of emergent pathogens with the capability for epidemic spread through the human population. In doing so, we aim to establish infection capabilities and diagnostic signatures for these new viruses, a new therapeutic strategy for these pathogens, and a better understanding of innate immunity to these agents.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Defining and Controlling Airway Disease
  • 批准号:
    10352375
  • 项目类别:
  • 资助金额:
    $94.5万
  • 财政年份:
    2019
  • 负责人:
    Michael J Holtzman
  • 依托单位:
Defining and Controlling Airway Disease
  • 批准号:
    10579266
  • 项目类别:
  • 资助金额:
    $94.5万
  • 财政年份:
    2019
  • 负责人:
    Michael J Holtzman
  • 依托单位:
Defining and Controlling Airway Disease
  • 批准号:
    9889988
  • 项目类别:
  • 资助金额:
    $94.4万
  • 财政年份:
    2019
  • 负责人:
    Michael J Holtzman
  • 依托单位:
TREM2 AND AIRWAY DISEASE
  • 批准号:
    9335933
  • 项目类别:
  • 资助金额:
    $44.94万
  • 财政年份:
    2016
  • 负责人:
    Michael J Holtzman
  • 依托单位:
海外基金